INTRODUCTION
Dual-specificity (threonine\tyrosine) protein phosphatases play a key role in the regulation of mitogen-activated protein kinase (MAPK) activity in eukaryotes ranging from yeast to humans [1] . These MAPK phosphatases (MKPs) act in direct opposition to MAPK kinases [' MKKs ' or MAP\ERK kinases (MEKs, where ' ERK ' represents extracellular signal-regulated kinase)], with the balance of these two activities determining the level of activation of the MAPK, and hence the biological outcome of signalling. Studies of MKPs in Saccharomyces cere isiae and Drosophila have shown that the expression of the genes encoding these enzymes is itself regulated by signalling via MAPK cascades, suggesting that they function as components of negative feedback loops [2, 3] .
Thus far, ten distinct dual-specificity MKPs have been identified and characterized in mammalian cells. These can be divided into two main groups on the basis of expression properties and subcellular localization [1] . The first, which includes MKP1\CL100\erp, MKP-2\hVH2\Typ1, hVH3\B23 and Pac-1, are encoded by growth factor-and\or stress-inducible genes, and these proteins are localized within the nucleus when expressed in mammalian cells. The second, which includes Pyst1\MKP-3\rVH6, Pyst2\MKP-X\B59, MKP-4, hVH5\M3\6, MKP-5 and MKP-7, are not encoded by immediate early genes and are Abbreviations used : ATF2, activating transcription factor-2 ; CRM, chromosomal region maintenance ; DAPI, 4,6-diamidino-2-phenylindole ; ERK, extracellular signal-regulated kinase ; FISH, fluorescence in situ hybridization ; GFP, green fluorescent protein ; HA, haemagglutinin ; HGF, hepatocyte growth factor ; JNK, c-Jun N-terminal kinase ; MAPK, mitogen-activated protein kinase ; MBP, myelin basic protein ; MEK, MAP/ERK kinase ; MKP, MAPK phosphatase ; NES, nuclear export signal ; p-NPP, p-nitrophenyl phosphate. 1 To whom correspondence should be addressed (e-mail S.Keyse!cancer.org.uk).
The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank2 and GSDB Nucleotide Sequence Databases under the accession number AJ430230. mammalian cells, the Pyst3 protein is predominantly cytoplasmic. Furthermore, leptomycin B causes a complete redistribution of the protein to the nucleus, implicating a CRM (chromosomal region maintenance)1\exportin 1-dependent nuclear export signal in determining the subcellular localization of this enzyme. Finally, whole-mount in situ hybridization studies in mouse embryos reveal that the Pyst3 gene is expressed specifically in the placenta, developing liver and in migratory muscle cells. Our results suggest that this enzyme may have a critical role in regulating the activity of MAPK signalling during early development and organogenesis.
Key words : catalytic activation, dephosphorylation, signal transduction, subcellular localization. localized predominantly within the cytoplasm. Recent excitement surrounding the MKPs has come from the finding that they exhibit exquisite substrate selectivity both in itro and in i o. This was demonstrated first for the cytosolic enzyme Pyst1\ MKP-3, which efficiently dephosphorylates the ' classical ' growth factor-activated MAPKs, ERK1 and ERK2, while exhibiting no activity towards stress-activated MAP kinases, such as p38α and c-Jun N-terminal kinase (JNK)1 [4, 5] .
The selective dephosphorylation of ERK2 by Pyst1\MKP-3 is accompanied by the formation of a physical complex between the two proteins [4] . Furthermore, ERK2 binding, which is mediated by the N-terminal non-catalytic domain of Pyst1\ MKP-3 [6] , is accompanied by catalytic activation of the phosphatase, as revealed by a greatly increased ability to hydrolyse pnitrophenyl phosphate ( p-NPP) in itro [7] . A combination of structural and biochemical studies suggest that catalytic activation results from the displacement of the general acid (Asp#'# in Pyst1) to a more favourable position for catalysis [8, 9] . On the basis of these results, specific recognition and binding to MAPKs, coupled with catalytic activation, has been proposed to mediate the substrate selectivity of all dual-specificity MKPs, and recent work lends support to this idea. The closely related enzymes Pyst2\MKP-X and MKP-4 also bind directly to ERK2, and undergo catalytic activation [7, 10] , and the inducible nuclear enzyme MKP-1\CL100 binds selectively to ERK2, JNK and p38α and is catalytically activated by these MAPK isoforms [11, 12] . For all of these MKPs, binding and catalytic activation exactly mirrors the substrate selectivity of the phosphatase towards MAPKs in i o.
Despite our expanding knowledge of the molecular basis of substrate recognition and catalysis by the mammalian MKPs, information about their physiological roles in mammalian cells and tissues is lacking. Studies in budding yeast and Drosophila suggest that these enzymes have key roles in the regulation of MAPK signalling in response to extracellular stimuli and during early embryonic development respectively [2, 3] . More recent studies in the nematode Caenorhabditis elegans have shown that a dual-specificity MKP encoded by lip-1 (lateral signal induced phosphatase-1) plays a pivotal role in the regulation of MAPK signalling in cell fate specification during vulval development [13] . Thus far, the only genetic studies of a mammalian dualspecificity MKP have involved the generation of mice that lack a functional copy of the inducible nuclear phosphatase MKP-1 [14] . The broad distribution of MKP-1 gene expression during mouse embryogenesis and development of tissues coupled with the observation that expression was localized to post-mitotic cell populations suggested an important role for MKP-1 in the process of cellular differentiation [15] . However, MKP-1-deficient mice are phenotypically normal and fertile, a result interpreted as indicating that other phosphatases must compensate for the loss of MKP-1 activity during development and in the adult animal [14] .
As part of ongoing studies to understand the physiological roles of the Pyst subfamily of cytosolic MKPs, we report the isolation and characterization of the murine Pyst3 gene and its protein product. Pyst3 encodes a dual-specificity MKP that is highly related to, but not identical with, the human MKP-4 phosphatase. We demonstrate that this protein interacts with, and is catalytically activated by, both mitogen-and stressactivated MAPK isoforms, and is able to dephosphorylate and inactivate both ERK1\2 and p38α MAPKs in i o. Like Pyst1, the Pyst3 protein is cytosolic, and we show that this localization is maintained by the activity of a chromosomal region maintenance (CRM)1-dependent nuclear export pathway. Finally, using whole-mount in situ hybridization we have determined the expression of Pyst3 during early mouse development. This reveals a very restricted distribution in which Pyst3 mRNA is found in the placenta, developing liver and migrating muscle cells. Our results suggest that Pyst3 may play a critical role in the regulation of MAPK signalling during early development and organogenesis.
EXPERIMENTAL Isolation and characterization of murine genomic clones encoding Pyst3
A 129Sv\lDashII mouse genomic library was screened using the full-length human Pyst2 cDNA as a probe, and positive plaques were identified and purified. The inserts were then excised, subcloned and analysed using a combination of restriction analysis, PCR and DNA sequencing. This screen yielded clones containing the murine homologue of Pyst2 and a 9 kb EcoRI fragment (2.1pTZ) containing a related gene, which was distinct from both Pyst1 and Pyst2. This gene was designated Pyst3.
Fluorescence in situ hybridization (FISH)
Metaphase spreads were prepared from normal mouse spleen as described by Monier et al. [16] . Pyst3 DNA (1 µg of 2.1pTZ) was labelled with biotin-14-ATP using a Bionick kit (Invitrogen, Carlsbad, CA, U.S.A.) and purified using a Sephadex G50 column, before ethanol precipitation with the addition of 50 µg of sheared salmon-sperm DNA and 50 µg of Escherichia coli tRNA. Hybridization and post-hybridization washes were performed exactly as described by Ragoussis et al. [17] . For detection of biotin-labelled probes, slides were incubated in avidin-FITC at 1 : 500 (Vector Laboratories, Burlingame, CA, U.S.A.) and then counterstained with 0.06 µg\ml DAPI (4,6-diamidino-2-phenylindole ; Sigma, Poole, Dorset, U.K.) in Citifluor (Citifluor Ltd, London, U.K.). Images were captured using a Zeiss Axioscop microscope equipped with a digital camera (Carl Zeiss Ltd, Stuttgart, Germany). Separate images of probe signal, banding pattern and counterstain were pseudo-coloured and merged using an Apple Powermac 8100 and Smartcapture software (Vysis Inc., Downers Grove, IL, U.S.A.).
Plasmids
All manipulations were performed using standard techniques [18] and plasmid structures were verified by DNA sequencing [19] . The complete Pyst3 open reading frame was assembled from the mouse genomic clone 2.1pTZ by overlap extension PCR [20] . The cDNA was then subcloned as an NdeI-XhoI fragment into the bacterial expression vector pET15b (Novagen, Madison, WI, U.S.A.), as an EcoRI-XhoI fragment into a modified pSG5 mammalian expression vector (Stratagene, La Jolla, CA, U.S.A.) encoding a C-terminal Myc-epitope tag [4] and as a BglII-SalI fragment into the green fluorescent protein (GFP)-containing mammalian expression vector pEGFP-N1 (Clontech, BD Biosciences, Palo Alto, CA, U.S.A.). Finally, Pyst3 was subcloned as an NdeI-XhoI fragment into the GAL4 DNA-binding and activation domain fusion yeast expression vectors pGBKT7 and pGADT7 (Clontech Matchmaker 3). GAL4 DNA-binding and activation domain fusion yeast expression vectors containing the various mitogen-and stress-activated kinase isoforms have been described previously [12] . Mammalian expression plasmids encoding haemagglutinin (HA)-tagged ERK1, p38α and JNK-1 have been described previously [4, 21] .
Northern blot analysis
$#P-Labelled probe was generated by random-primed labelling [22] Cell culture, transfection and fluorescence microscopy COS1 and HeLa cells were maintained in Dulbecco's modified Eagle's medium (' DMEM ') supplemented with 10 % (v\v) foetal bovine serum and transfected using a standard calcium phosphate method, as described previously [4] . Localization of the Pyst3 protein in HeLa cells was determined by transfection of 2 µg of pEGFP-N1-Pyst3, which encodes a C-terminal fusion between Pyst3 and GFP, or empty vector as a control. Cells were then cultured for 48 h. To treat cells with leptomycin B (kindly given by Dr Minoru Yoshida, University of Tokyo, Japan), the drug was added at a final concentration of 10 µg\ml for the final 3 h of culture. Cells were then washed with PBS and fixed for 5 min in chilled 4 % (w\v) paraformaldehyde. Following extensive washing with PBS, nuclei were counterstained with DAPI. Cell staining was observed and photographed using a Zeiss Axiovert S100 microscope fitted with a digital camera (Hamamatsu Characterization of a murine mitogen-activated protein kinase phosphatase Photonics, Bridgewater, NJ, U.S.A.) by fluorescence microscopy using excitation\emission filters for FITC and DAPI. Images were processed using Openlab (Improvision, Warwick, U.K.) and Photoshop (Adobe, San Jose! , CA, U.S.A.). At least 50 GFPpositive cells were examined in each experiment, and staining patterns were entirely consistent with the representative cells photographed.
Antibodies, immunoblotting and immunoprecipitations
The anti-Pyst3 antibody was produced by immunizing sheep with the synthetic peptides NH # -Ser-Asp-Phe-Ser-Asp-Ala-GluSer-Glu-Ala-Asp-Arg-Asp-Thr-Leu-Ser-Cys-Gly-Leu-Asp-SerGlu-Asn-Thr-Thr-Ser-COOH (corresponding to residues 233-258 of the Pyst3 protein) and NH # -Ser-Thr-Val-Ser-Asp-ProPro-Ser-Phe-Phe-Thr-Thr-Pro-Thr-Ser-Asp-Gly-Val-Phe-GluLeu-Asp-Pro-Thr-COOH (corresponding to residues 425-448 of the Pyst3 protein) coupled with keyhole-limpet haemocyanin (Pierce, Rockford, IL, U.S.A.). Purified Pyst3 protein expressed in E. coli or 5 µg of total protein from freshly prepared mouse tissue lysates was separated by SDS\PAGE and transferred to PVDF membrane (Immobilon-P ; Millipore Corp., Bedford, MA, U.S.A.) before immunoblotting with the anti-Pyst3 antiserum using standard techniques [23] . The phosphorylation status of ERK2 was analysed by Western blotting using rabbit polyclonal antibodies specific for either pThr")$-ERK2 (Promega Corp., Madison, WI, U.S.A.) or pTyr")&-ERK2 (Calbiochem, La Jolla, CA, U.S.A.). As a loading control, blots were also probed with an anti-ERK2 monoclonal antibody (Zymed Laboratories, San Francisco, CA, U.S.A.). HA-tagged ERK1, p38α and JNK1 were detected in transfected COS1 cell lysates by Western blotting using the anti-HA monoclonal antibody 12CA5, and Myc-tagged Pyst3 was detected using the anti-Myc monoclonal antibody 9E10. HA-tagged MAPKs were immunoprecipitated from transfected COS1 cell lysates as described previously [4] .
Expression and purification of recombinant Pyst3
The pET15b expression plasmid encoding His-tagged Pyst3 was transformed into the host bacterial strain BLR-DE3 (Novagen, Madison, WI, U.S.A.) using standard techniques. Following expression, the protein was purified using nickel-agarose resin (Ni# + -nitriloacetate ; Qiagen Inc., Valencia, CA, U.S.A.) under denaturing conditions and refolded by sequential dialysis exactly as described previously [24] .
Protein phosphatase assays
Phosphatase activity and catalytic activation of recombinant Pyst3 was determined using p-NPP hydrolysis at 25 mC. This was measured in 96-well plates in 200 µl of 50 mM imidazole, pH 7.5, containing 10 mM dithiothreitol, 20 mM p-NPP and the indicated amount of Pyst3 protein supplemented with either 1 mM sodium orthovanadate or the indicated amount of various purified recombinant MAPKs. Reaction rates were monitored by absorbance at 405 nm, in a microplate reader (Bio-Rad Laboratories, Hercules, CA, U.S.A.) as described previously [10] , and initial rates of p-NPP hydrolysis were determined using Microplate Manager III-Vs 1.57 (Bio-Rad Laboratories).
To measure dephosphorylation of ERK2 by Pyst3 in itro, 500 ng aliquots of recombinant activated ERK2 (kindly provided by Dr Neil McDonald, Cancer Research UK, Lincoln's Inn Fields, London, U.K.) were incubated with increasing amounts of recombinant Pyst3 protein for 30 min at 37 mC. Following incubation, aliquots of each reaction equivalent to 5 ng of recombinant ERK2 were analysed using SDS\PAGE, transferred to nitrocellulose, and the phosphorylation status of the ERK2 was determined by Western blotting, as described above.
Kinase assays
The activity of Pyst3 towards HA-tagged ERK1, p38α and JNK1 MAPKs was determined by co-transfection of COS1 cells with 2 µg of expression vector encoding HA-tagged MAPK isoforms in combination with increasing amounts of pSG5-Pyst3-Myc. Following expression, cells were exposed to an appropriate activating stimulus (serum for ERK1 ; anisomycin for JNK1 and p38α), followed by immunoprecipitation and assaying of kinase activities, exactly as described previously [10] .
Yeast two-hybrid assays
Plasmids encoding GAL4 DNA-binding domain and activation domain fusion proteins were transformed into the yeast strains PJ69-4A and PJ69-4α respectively, according to the manufacturer's instructions (Clontech). Semi-quantitative analysis of two-hybrid interactions was performed using a β-galactosidase assay, according to the manufacturer's instructions (Clontech). To ensure all protein-kinase interactions were detected, binding capability was assessed using each kinase isoform expressed as GAL4 DNA-binding domain and activation domain fusions, where possible.
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed according to a protocol modified from that of Wilkinson [25] . Embryos were incubated overnight with 1 µg of digoxigenin-labelled cRNA probe, generated by run-off transcription with T7 polymerase from a pBluescript construct containing a 635 bp XbaI-PstI restriction fragment derived from the 3hUTR of Pyst3. Photographs were taken on a Leitz dissecting microscope equipped with an Olympus 35 mm camera. Images were scanned and processed using Photoshop (Adobe).
RESULTS

Isolation and characterization of the murine Pyst3 gene
High-stringency screening of the mouse 129Sv\lDashII genomic library with the full-length human Pyst2 cDNA yielded a number of positive signals. Upon further characterization of these clones, several were found to contain a murine gene related to, but distinct from, both Pyst1 and Pyst2, and this was designated Pyst3. The Pyst3 gene spans approx. 4.5 kb, and comprises three coding exons interrupted by two introns ( Figure 1A ). In terms of gene structure, both the positions and the phase of the two introns are conserved when compared with the human Pyst1 and Pyst2 genes [10] .
Determination of the complete coding sequence of Pyst3 reveals that it specifies a protein of 448 amino acids, and sequence comparison indicates that it is most similar (85 % identity ; 87 % similarity) to the human enzyme MKP-4 ( Figure  1B) . However, when compared with MKP-4, Pyst3 contains an insertion of 63 amino acids within the N-terminal non-catalytic domain. This insertion comprises mainly repeats of the sequence Ala-Glu-Ala-Lys, and lies between two conserved regions of sequence similarity found in all dual-specificity MKPs and the cdc25 phosphatase [26] .
PCR analysis of DNAs from a panel of radiation hybrids has mapped the human MKP-4 gene to chromosome Xq28 [27] . FISH analysis using our Pyst3 genomic clone maps the mouse gene to the X chromosome in region B ( Figure 1C) , which is syntenic with Xq28 [28] . Furthermore, we have performed a Northern blot analysis on mRNA derived from a range of adult mouse tissues. Using a probe from the 5h end of the Pyst3 cDNA, we were able to detect a single mRNA species of approx. 3.8 kb, which, of the ten adult tissues tested, is expressed only in the kidney (Figure 2) . Interestingly, an extensive tissue Northern blot analysis of the human MKP-4 transcript also revealed that expression was restricted to the adult kidney [27] .
Pyst3 interacts with both mitogen-and stress-activated MAPKs in vivo
The specific dephosphorylation of ERK2 by Pyst1 and Pyst2 is accompanied by the formation of a tight physical complex between phosphatase and MAPK [4, 10] . The N-terminal noncatalytic domain of Pyst1 mediates ERK2 binding, since removal of this domain abrogates substrate selectivity in i o [6] . Furthermore, this binding is direct, as demonstrated by GST ' pulldown ' experiments using purified proteins [7] . Pyst3 contains an insertion of 63 amino acids within this region, and it was important to determine whether Pyst3 was capable of interaction with MAPKs and also the full extent of its binding specificity. To answer this question, a yeast two-hybrid assay was used to determine the specificity of interactions between Pyst3 and a comprehensive panel of nine distinct mitogen-and stress-activated MAPK isoforms in i o. In this assay, a DNA-bindingdomain-fused ' bait ' protein interacts with an activation-domain- 
Figure 3 Analysis of two-hybrid interactions between Pyst3 and a panel of mitogen-and stress-activated MAPK isoforms
(A) pGBKT7.Pyst3 was transformed into PJ69-4A and mated with PJ69-4α expressing the GAL4 activation domain (AD) fusions pGADT7.ERK1, pGADT7.ERK2, pGADT7.ERK3, pGADT7.ERK5, pGADT7.ERK7, pGADT7.JNK1, pGADT7.p38γ and pGADT7.p38δ. p38α was expressed in PJ69-4A as a GAL4 DNA-binding domain (BD) fusion (pGBKT7.p38α), and mated with pGADT7.Pyst3 transformed into PJ69-4α. Yeast diploids expressing both BD and AD fusions were selected on synthetic dropout (SD) media deficient in leucine and tryptophan. kLeu/kTrp positives were re-streaked on to SDkLeu/kTrp/kHis/kAde. Protein-protein interactions were assessed by growth on this selective medium. fused partner protein to reconstitute a sequence-specific transcriptional activator. The interacting pair then binds a specific sequence motif, thus activating transcription of at least two separate reporter genes. In our case, protein-protein interactions were detected by the activation of GAL4-dependent ADE2\ HIS3\LacZ reporters. Activation of HIS3 and ADE2 was assessed by selection on synthetic dropout medium deficient in histidine and adenine ( Figure 3A) , and the strength of the interactions was quantified in a β-galactosidase assay ( Figure  3B ). Western blot analysis using GAL4-specific antibodies (Clontech) verified expression of each of the MAPK-fusion proteins used in the screen (results not shown). Pyst3 specifically interacts with ERK1, ERK2 and p38α with a rank order of binding strength ERK2 ERK1 p38α. Very weak interactions, which were not revealed by growth on selective media, were also detected with JNK1, ERK3 and ERK5, whereas no significant interaction was seen with ERK7, p38δ or p38γ ( Figure 3B ). We consistently found that ERK1 has a lower affinity for Pyst3 when compared with ERK2, and this was also the case when either Pyst1 or MKP-1\CL100 was used as the bait in these assays [12] .
Pyst3 dephosphorylates ERK2 in vitro
Pyst3 was expressed as a His-tagged fusion protein and purified from bacteria ( Figure 4A, lane 1) . A polyclonal antiserum raised against two C-terminal Pyst3 peptides detects this recombinant protein ( Figure 4A, lane 2) , and, in agreement with our tissue expression data (Figure 2 ; also see Figure 8 ), also recognizes endogenous Pyst3 protein in lysates of mouse placenta and adult kidney, but not of adult liver ( Figure 4A, lanes 3-5) . The Pyst3 protein is catalytically active, since it hydrolyses p-NPP, and this activity is abolished by sodium orthovanadate, a selective inhibitor of protein tyrosine phosphatases ( Figure 4B ). To determine whether Pyst3 has activity towards MAPK, recombinant activated ERK2 was incubated with increasing amounts of purified enzyme, and the phosphorylation state of the ERK2 was monitored using antibodies which specifically recognize either the phosphothreonine or phosphotyrosine residues within the Thr-Xaa-Tyr motif. Consistent with the ability of Pyst3 to interact with ERK2 in our two-hybrid assays, our results clearly show that Pyst3 dephosphorylates both residues with approximately equal efficiency ( Figure 4C ), and thus acts as a dualspecificity MKP in itro.
Catalytic activation of Pyst3 by MAPKs
Significant progress in understanding MKP function was made with the demonstration that the catalytic activity of MKP-3 (Pyst1) could be specifically increased on binding to its substrate ERK2 in itro [7] . Catalytic activation by MAPK isoforms has subsequently been demonstrated for Pyst2\MKP-X [10] , CL100\ MKP-1 [11, 12] and MKP-2 [29] . To determine whether Pyst3 is activated in this way, p-NPP hydrolysis was monitored in the absence or presence of increasing amounts of recombinant ERK2, p38α and JNK1 ( Figure 5A ). The activity of Pyst3 is stimulated in a dose-dependent manner by these three MAPKs, with ERK2 being clearly the most potent. In order to determine the specificity of Pyst3 catalytic activation, we extended our study to a panel of six distinct recombinant mitogen-and stress-activated MAPK isoforms ( Figure 5B ). In addition to ERK2, p38α and JNK1, Pyst3 activity was also increased on incubation with ERK5. Although these stimulations are not in the order of the 20-30-fold effects seen on incubation of Pyst1\MKP-3 with ERK2, they would appear to be significant, since incubation with the closely related p38 MAPK isoforms γ and δ did not cause a significant increase in the catalytic activity of Pyst3. Interestingly, although p38α, JNK1 and ERK5 all increase the activity of Pyst3, of these only p38α appears to be able to interact strongly 
Figure 7 Pyst3 is localized in the cytoplasm of mammalian cells by a leptomycin B-sensitive mechanism
Localization of the Pyst3 protein in HeLa cells was determined by transfection of 2 µg of pEGFP-N1-Pyst3, which encodes a C-terminal fusion between Pyst3 and GFP. Cells were then cultured for 48 h before fusion protein expression was observed by fluorescence microscopy using excitation/emission filters for FITC (GFP ; A and D) and DAPI (B and E) or phase contrast microscopy (C and F). To treat cells with leptomycin B (D-F), the drug was added at a final concentration of 10 µg/ml for the final 3 h of culture. At least 50 GFP-positive cells were examined for each transfection, and staining patterns were entirely consistent with the representative cells photographed here.
with Pyst3 in i o ( Figure 3A) . However, a similar mismatch between binding and catalytic activation has been noted for the inducible nuclear phosphatase MKP-2 [29] .
Inactivation of MAPK isoforms by Pyst3 in mammalian cells
Our yeast two-hybrid data indicate that Pyst3 is likely to interact with ERK1\2 and p38α in mammalian cells, and both kinases are also able to catalytically activate Pyst3 in itro. However, other MAPKs, including JNK, also stimulate the activity of Pyst3 in itro and therefore could be substrates for Pyst3. In order to determine the substrate selectivity of Pyst3 in i o, cotransfection experiments were performed in which increasing amounts of Myc-tagged Pyst3 were expressed in COS1 cells, together with HA-tagged ERK1, JNK1 or p38α. Following activation of the respective kinases using an appropriate stimulus, cells were lysed and immunocomplex kinase assays were performed to determine the effects of Pyst3 expression on activity. Pyst3 clearly acts potently on ERK1 and p38α even at the very lowest levels of expression ( Figures 6A and 6C) . In contrast, Pyst3 elicits markedly lower inhibition of JNK, and is unable to abolish the activity of this kinase even at the highest levels of Pyst3 expression ( Figure 6B ). Thus it would appear that, at least with respect to p38α and JNK1, binding in the yeast two-hybrid assay is a better predictor of substrate selectivity for Pyst3 than is catalytic activation of the phosphatase in itro.
Pyst3 is localized in the cytoplasm of mammalian cells by a leptomycin B-sensitive mechanism
The Pyst1 (MKP-3) and Pyst2 (MKP-X) proteins are localized predominantly in the cytoplasm when expressed in mammalian cells [4, 10, 30] . In contrast, inducible MKPs, such as MKP-1, MKP-2 and Pac-1, are found in the cell nucleus [31] [32] [33] . However, nothing is yet known about the mechanisms determining the
Figure 8 Pyst3 expression during murine embryogenesis
Expression of Pyst3 in developing embryos at the indicated stages from E7-E11 was determined by whole-mount in situ hybridization. Embryos before stage E9 were either left completely within the decidua (E7-E7.5), or removed from the yolk-sac to separate embryonic and placental expression patterns (E8.5). Thereafter, embryos were dissected completely clear of the extra-embryonic tissues (E9-E11). The E11 arrowhead indicates the telencephalic mid-line expression domain. In each case, the embryo has been photographed from the left side of the main axis. Abbreviations : ch, chorion ; ec, ectoplacental cone ; fg, foregut ; fl, forelimb ; hl, hind-limb ; ht, heart ; lb, liver bud ; li, liver diverticulum ; md, mandible ; vt, ventral telencephalon. differential localization of these enzymes, or its physiological significance. An expression vector encoding Pyst3 fused to GFP was transfected into HeLa cells and the expressed protein was found to be predominantly cytoplasmic ( Figure 7A ). Identical results were obtained when this fusion protein was expressed in COS1 cells, and treatment of cells with serum or anisomycin, classical agonists for mitogen and stress-activated MAPKs respectively, had no effect on Pyst3 localization (results not shown).
Two leucine-rich sequences reminiscent of nuclear export sequences (NESs) found in proteins such as MEK1, PKIα and Rev were reported as being present in the non-catalytic Nterminus of rVH6\Pyst1 [34] , and sequence comparison shows that these are also conserved in Pyst2 and MKP-4 [10] . NESs are responsible for mediating interactions with the nuclear export protein CRM1, but to date it has not been demonstrated that the cytoplasmic localization of Pyst family proteins is dependent on this export pathway. The fungal toxin leptomycin B blocks nuclear export of proteins containing a leucine-rich NES by preventing the binding of the NES to the export receptor CRM1 [35] [36] [37] [38] . Treatment of cells expressing Pyst3-GFP with leptomycin B results in almost complete re-localization of Pyst3 to the nucleus, indicating that cytoplasmic localization of Pyst3 is CRM1-dependent ( Figure 7B, lower panels) .
Expression of Pyst3 in developing mouse embryos
Although our understanding of the MKPs has increased greatly in recent years, very little is known of their physiological roles in mammalian cells and tissues, as studies to date have mostly concentrated on biochemical and structural aspects of their function. Expression studies have, in the main, relied on tissue Northern blots and expression profiles in cultured cell lines. Differential regulation of various MKPs has been shown in the rat brain following excitotoxic cell death in seizures [39, 40] , whereas limited embryonic expression patterns using radiolabelled riboprobes on sectioned material have been obtained for the murine MKP-1\CL100 orthologue 3CH134\erp [15] .
Using whole-mount in situ hybridization, we have analysed the expression pattern of Pyst3 in intact mouse embryos from stage E7 through to stage E11, a period spanning establishment of the body plan and development of most major organ systems. Three main zones of expression were identified by these methods. In the earliest phases from stages E7 to E8 (Figure 8 ; stages as indicated), Pyst3 is expressed with increasing levels in the ectoplacental cone and chorion components of the developing placenta. This expression continues through E9 and E10, although by the later stages the hybridization signal declines slightly (results not shown). The second domain of expression commences at E8.5, in a group of cells of the ventral foregut endoderm induced by signals from the cardiac mesoderm to acquire a hepatocytic fate [41] . Expression of Pyst3 increases in these cells through E9, coincidently with their migration into the septum transversum region to become the liver diverticulum. These cells continue to proliferate throughout the stages examined, during which time expression of Pyst3 is maintained.
Finally, expression of Pyst3 commences in diverse groups of future muscle cells from E9. This includes transient expression in both dorsal and ventral muscle groups of fore-and hind-limbs at stages E9-E10, although the forelimb expression is lost entirely by E11, and is limited to a group of ventral muscle cells in the hind-limbs at this stage. At E10, Pyst3 is expressed in small groups of cells beneath and lateral to the developing liver, which give rise to musculature of the diaphragm. Expression of Pyst3 is evident from E9 in the face, expanding from a group of cells in the mandible at E10 to occupy locations around the oral cavity comprising musculature derived from the hypoglossal cord by E11. At E11, expression is also detected in the ventral telencephalon, and additionally in a punctate central domain at the base of the mid-line separating the telencephalic hemispheres.
DISCUSSION
The murine Pyst3 gene encodes a dual-specificity MKP that is most highly related to the human enzyme MKP-4, and this, coupled with the mapping of Pyst3 to a region of the Xchromosome syntenic with the location of the human gene, strongly suggests that Pyst3 and MKP-4 are orthologous. The major difference between Pyst3 and MKP-4 is the presence in the former of an insertion of 63 amino acids within the N-terminal non-catalytic domain of the protein essential for substrate binding and recognition. Surprisingly, this insertion does not impair the ability of Pyst3 to interact with MAPKs in i o, nor does it affect the catalytic activation of Pyst3 on incubation with MAPKs in itro. The solution structure of the N-terminal ERK2-binding domain of the related enzyme Pyst1\MKP-3 was reported recently [42] . This reveals that the insertion in Pyst3 is located within one of two β-α-β motifs, which are in the most conserved parts of the protein. However, within this motif the insertion lies in a highly variable region forming a surface loop, and it must be presumed that this can be accommodated without affecting the overall fold and function of the ERK2-binding domain.
We have used the yeast two-hybrid assay to probe interactions between Pyst3 and a panel of nine distinct MAPKs in i o, and find that the strongest interaction partners for this enzyme are ERK1 and ERK2, with a much weaker interaction observed with p38α. Recombinant Pyst3 also undergoes catalytic activation and, in agreement with our binding data, ERK2 is the most potent activator of the enzyme. However, unlike Pyst1\ MKP-3 and Pyst2\MKP-X, where activities are increased between 12 and 30-fold on incubation with ERK2 [4, 10] , maximal stimulation of Pyst3 is only 3.2-fold. Stress-activated MAPKs, such as p38α and JNK1, also increase Pyst3 activity, but only with a factor of between 1.5 and 1.8-fold. The significance of these small effects is questionable in relation to the substrate selectivity of Pyst3, because our in i o assays show that Pyst3 inactivates ERK1 and p38α, but not JNK1. Thus our interaction data are a more reliable indicator of the ability of Pyst3 to inactivate stressactivated MAPK isoforms than the ability of these enzymes to stimulate the in itro activity of Pyst3 towards p-NPP. Similar discrepancies have been observed between MAPK binding and catalytic activation for the dual-specificity phosphatases MKP-5 and MKP-2 [29, 43] . Interestingly, the human MKP-4 enzyme was reported to be capable of dephosphorylating JNK [27] . However, as stated above, we can find no evidence for binding or significant inactivation of JNK by Pyst3. We conclude that Pyst3 is most likely to target ERK1 and ERK2 in i o, but a role for this enzyme in the regulation of signalling via the p38\MAPK pathway cannot be excluded.
It has become clear that the outcome of MAPK signalling is determined not only by the magnitude and duration of activation, but also by the subcellular localization of the MAPK itself [44, 45] . Thus far, scant attention has been paid to the mechanisms determining the subcellular localization of critical regulators such as the MKPs, and how this relates to the function of these enzymes. All members of the Pyst subfamily studied thus far are predominantly cytoplasmic when expressed in mammalian cells. Although the presence of canonical leucine-rich NESs has been noted [10, 34] , nothing is yet known about the mechanisms which govern localization of these proteins. We have demonstrated that cytoplasmic localization of Pyst3 is maintained by a CRM1-dependent nuclear export pathway. Furthermore, the size of our Pyst3-GFP fusion protein and the observation that it becomes exclusively nuclear in the presence of leptomycin B indicates that this export pathway must normally overcome an opposing active process of nuclear import to maintain the localization of Pyst3. Experiments are currently underway to determine whether the Pyst3 protein is capable of ' shuttling ' between these two subcellular compartments, and to define the sequence motif(s) involved in these critical export and import pathways.
The generation of knockout mice is a powerful tool to probe gene function. As part of this process, it is essential to perform a detailed survey of the expression pattern of the gene during embryogenesis in order to allow any eventual phenotype to be interpreted on the basis of when and where the gene of interest is expressed. To this end, we instigated an in situ hybridization analysis of murine Pyst3 expression during a range of embryonic stages covering important organogenic and morphogenic events from E7 through to E11. Pyst3 is expressed in a strikingly specific range of locations both within the developing embryo and in its extra-embryonic tissues. Initially, Pyst3 is found in the trophoblast from the very earliest stages examined. This structure contributes to the labyrinthine layer of the placenta by E10, which constitutes the principal exchange surface between maternal and embryonic circulatory systems from this stage onwards [46] .
Loss of function of a number of gene products functioning either as activators or components of MAPK-signalling cascades results in ablation or substantial impairment of labyrinth formation, indicating that MAPK signalling has a crucial role in the regulation of cell growth and differentiation in these cell layers. These include hepatocyte-growth-factor (HGF), the HGF receptor c-Met, the son-of-sevenless 1 (' Sos-1 ') gene product, MEK1, the MAPK p38α and its upstream activator MEK kinase-3 (' MEKK3 ') [46] [47] [48] . We have demonstrated that Pyst3 is a potential regulator of both ERK1\2 and p38α MAPKs, and this, coupled with the expression pattern of Pyst3, suggests an important role for this enzyme in placental development.
The second major expression zone for Pyst3 is in the developing liver, again suggesting a role for Pyst3 in regulation of organogenesis. Initiation of the liver occurs at E8, when signals emanating from the cardiac mesoderm induce ventral cells of the underlying foregut endoderm to proceed along a path of hepatocyte cell fate. This bud of cells then proliferates and migrates into the surrounding septum transversum mesenchyme, and the entire domain becomes delineated or encapsulated as the liver bud grows rapidly into an organ [49] . Proliferation of hepatocytes following initial specification relies on reciprocal signalling between mesenchymal and endodermal cells expressing HGF and its receptor c-Met respectively [48] . Fibroblast growth factor (' FGF ') signals from the cardiac mesoderm have been demonstrated to be both necessary and sufficient to induce a hepatic fate within the endoderm [41] . Pyst3 is expressed from the very earliest stages that these signals are known to be effective, and it is possible that Pyst3 is induced directly as a very early marker of this event. The p38 MAPK pathway has also been implicated as a negative regulator of hepatocyte proliferation [50] and its activity is maintained at negligible levels throughout the early phases of liver development, during which time the cells undergo considerable proliferation. It is possible, given our findings both in i o and in itro, that Pyst3 may be the implied negative regulator of p38 activity in the liver, and thus a promoter of hepatocyte proliferation during embryonic development.
The third major zone of Pyst3 expression in the stages examined comprises lineages of migratory skeletal-muscle cells originating in the lateral dermamyotomal lips of the somites. These provide musculature for the tongue, diaphragm and limbs. All of these cells depend on signalling via the c-Met receptor for correct migration [47, 51] . Conversion of muscle cells from committed precursors into differentiated myotubes requires the activity of both ERK1\2 and p38 MAPKs [34, 52] . This strongly suggests a role for Pyst3 in inhibition of differentiation of migratory muscle cells via blockade of ERK1\2 and\or p38 signals in i o.
In conclusion, we have isolated and characterized a mouse gene encoding a functional dual-specificity MKP that is most closely related to the human enzyme MKP-4. We have demonstrated that this enzyme interacts with and inactivates both mitogen-and stress-activated MAPK isoforms in i o, and shown that the cytoplasmic localization of the enzyme is maintained by a CRM1-dependent nuclear export pathway. Finally, our determination of the pattern of Pyst3 expression in the developing mouse embryo suggests a role for this enzyme in the regulation of MAPK signalling during placental, hepatic and muscular development. In particular, the tight correlation between Pyst3 expression and domains of c-Met expression strongly suggests that Pyst3 may lie downstream of, and regulate signals transduced by, the c-Met receptor itself.
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